Dr. Hal Gunn demonstrates to patients how to administer QBECO SSI, an investigational new treatment for Crohn’s disease. Qu Biologics is actively recruiting 60 adults with moderate to severe Crohn’s disease for a Phase 1/2 clinical trial of this potential new treatment. Qu Biologics develops Site Specific Immunomodulators (SSIs), a novel class of immunotherapies that aim to ‘reboot’ the body’s innate immune system.
Dr Hal Gunn demonstrates administration QBECO SSI
